Details checkedClinical trial listing onlyCheckedregistry

Ospedale San Raffaele Tirzepatide Study in Wolfram Syndrome Type 1

Also known as: Tirzepatide, Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1, NCT05659368

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Unknown

Target Gene

—

Route / Mode

Subcutaneous injection

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Italy

Population

genetic, syndromic, pediatric, adult

Trial IDs

Mechanism

Phase 2 institution-led study of once-weekly subcutaneous tirzepatide monotherapy in Wolfram syndrome type 1, a rare syndromic disease with hearing-loss relevance.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

Verified as a real Wolfram syndrome type 1 tirzepatide study. It is included as a hearing-adjacent syndromic record rather than a dedicated hearing-loss therapeutic program; the registry status is Unknown and estimated completion has passed.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT05659368

Open

Key Events

2024-01-01

Registry lists actual study start for tirzepatide monotherapy in Wolfram syndrome type 1

Clinical Trials (1)

NCT05659368

Data Checks